Table 2 Summary of symptoms and days to resolution of symptoms reported across association studies and incidence studies
From: Systematic review of influenza resistance to the neuraminidase inhibitors
Study | Resistant patients | Sensitive patients | ||
|---|---|---|---|---|
| Â | n | Reported symptoms and durations | n | Reported symptoms and durations |
Association studies | Â | Â | Â | Â |
Buchholz (2009) 48 | 11 | Duration of sick leave: Median: 7 days IQR: 6 to 14 | 26 | Duration of sick leave: Median: 7 days IQR: 7 to 10 |
Buchholz (2009) 48 | 38 | Days confined to bed: Median: 3.5 days IQR: 2 to 7 | 93 | Days confined to bed: Median: 3 days IQR: 2 to 5 |
Dharan (2009) 50 | 49 | Activities limited: 1-7 days Median: 4 days | 97 | Activities limited: 1-30 days Median: 4 days |
Dharan (2009) 50 | 38 | Missed work or school: 1-10 days Median: 4 days | 97 | Missed work or school: 1-30 days Median: 4 days |
Incidence studies | Â | Â | Â | Â |
Kiso (2004) 15 | 9 | Duration of fever: 2-7 days Median = 3 days | 41 | Duration of fever: 1-6 days Median = 3 days |
Hatakeyama (2007) 41 | 1 | Duration of fever: 2 days | 76 | Mean duration of fever: 2.4 days |
Stephenson (2009) 43 | 4 | Duration of fever: 5-6 days Full recovery after: 9-10 days | 60 | Authors commented no difference observed |
| Â | Â | Â | Â | between resistant and sensitive patients |